Key Biden administration decisions on how to implement the US Medicare program’s new drug price negotiation authorities could help the government in its attempts to quash the pharmaceutical industry's and other challenges to the Inflation Reduction Act program in court, legal experts say.
These decisions came in recent Medicare and Internal Revenue Service guidance that were issued after many of the industry's challenges...





